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Introduction {#sec006}
============

Colonoscopy is the gold-standard diagnostic tool for colorectal cancer (CRC) and precancerous lesions. However, the adenoma miss-rate (AMR) ranges from 6% to 27%\[[@pone.0231880.ref001]\]. It is noteworthy that precancerous lesions with a flat morphology, smooth surface, indistinct boundaries or isochromatic with background are more susceptible to be missed\[[@pone.0231880.ref002], [@pone.0231880.ref003], [@pone.0231880.ref004]\]. Given these subtle features of morphology and color, nonpolypoid laterally spreading tumors (LSTs) and sessile serrated adenoma/polyps (SSA/Ps) are among the easist-to-miss lesions\[[@pone.0231880.ref005], [@pone.0231880.ref006]\]. LSTs extend laterally along the colon wall without a polypoid morphology\[[@pone.0231880.ref007], [@pone.0231880.ref008]\]. It could be categorized into 2 types as granular type (LST-G) and non-granular type (LST-NG). The LSTs have a remarkable high risk of malignancy transformation, studies have shown that 63.1% of the investigated LSTs are adenomas with villous structures\[[@pone.0231880.ref006]\] 20.9%-36.0% of LSTs were found to have high grade intraepithelial neoplasia (HGIN), moreover, LSTs can also develop into a submucosal invasive cancer\[[@pone.0231880.ref006], [@pone.0231880.ref009], [@pone.0231880.ref010]\]. Serrated polyps (SPs) are the second most common type of colon polyps, among which, SSA/Ps take about 10--20% of SPs\[[@pone.0231880.ref011], [@pone.0231880.ref012]\] and 5--10%\[[@pone.0231880.ref005]\] of lesions found during screening colonoscopy. SSA/Ps are a high-risk precursor for CRC via serrated pathway\[[@pone.0231880.ref005], [@pone.0231880.ref013], [@pone.0231880.ref014]\], the estimated 10-year risk for CRC transformation from SSA/Ps ranges from 2.56% to 4.43% according to the existence of cytological dysplasia\[[@pone.0231880.ref015]\] and are dependent on the size\[[@pone.0231880.ref016]\]. The detection of SSA/Ps via colonoscopy is always difficult due to the pale color and flat morphology\[[@pone.0231880.ref017]\].

Evidence has shown that with a second party observing the monitor synchronously during colonoscopy, polyp detection rate could be improved by means of addressing the unrecognized polyps within the visual field\[[@pone.0231880.ref001]\]. However, in comparison with polypoid lesions, to detect LSTs and SSA/Ps is a more challenging task, it is likely that adding an additional human observer would not completely overcome the challenges. Thanks to the breakthrough of artificial intelligence (AI), ideally, real-time computer aided detection (CADe) system during colonoscopy with a comparable detection capability to expert endoscopist could process each frame of the endoscopic video stream and alert any detected targets synchronously, this is a more consistent and reliable set-up than a human assistant\[[@pone.0231880.ref018]\], because CADe system would consistently analyze every corner of the screen and not miss any single frame of a suspicious lesion. Our CADe system has been previously demonstrated to improve polyp and adenoma detection rate in real world colonoscopy setting\[[@pone.0231880.ref019]\]. The CADe system was especially developed to capture and identify the local features of colon polyps of variant histology and thus to achieve a high sensitivity and specificity. However, the large-scaled specialized test of such CADe system on LSTs and SSA/Ps is lacking. Therefore, the aim of this study was to investigate the detection performance of the local-feature-prioritized CADe system on LSTs and SSA/Ps.

Materials and methods {#sec007}
=====================

CADe system (EndoScreener, Shanghai Wision AI Co., Ltd. China) {#sec008}
--------------------------------------------------------------

The real-time automatic polyp detection system\[[@pone.0231880.ref019]\] ([Fig 1](#pone.0231880.g001){ref-type="fig"}) was developed on a deep learning architecture, which was previously validated to have a per-image sensitivity of 94.38%, per-image specificity of 95.92% and an area under the receiver operating characteristic curve of 0.984 on consecutive colonoscopy images. In addition, the algorithm has a per-polyp sensitivity of 100.00% (per-image sensitivity of 91.64%) and a per-image specificity of 95.40% in colonoscopy videos.

![Schematic of the automatic polyp detection algorithm \[[@pone.0231880.ref019]\].\
a. Original colonoscopy image frames generated during regular colonoscopy procedures. b. Deep convolutional neural network (CNN): SegNet architecture. (<http://mi.eng.cam.ac.uk/projects/segnet/>), which calculates the probability of. belonging to a polyp for each pixel in the input colonoscopy image frame. c. Probability map, which showed the probability of belonging to a polyp (color blue represents probability = 0, color red represents probability = 1, color in between represents 0\<probability\<1), for each pixel in the input image frame. d. Based on the probability map, hollow blue boxes are added to the original image, in order to highlight the polyp areas for the observing clinicians.](pone.0231880.g001){#pone.0231880.g001}

In the preliminary study, the algorithm was trained on 5545 colonoscopy images with variant polyp morphology and histology, among which there were 103 images of 69 LSTs, including 56 images of 34 LST-G and 47 images of 35 LST-NG.

To better distinguish the intra-class and inter-class variability and thus to achieve high sensitivity, specificity and to effectively detect partially occluded polyps, this network structure of the algorithm is characterized by its small receptive fields that extract the local visual features of the input image, as well as the high nonlinearity of its consecutive convolution layers without pooling\[[@pone.0231880.ref019]\].

The system provides a per-pixel labeling of its detected area on each processed frame.

Detection validation {#sec009}
--------------------

This study was conducted in the endoscopy center of Sichuan provincial people's hospital, China.

We retrospectively collected images of LSTs and video clips of SSA/Ps from the database of our center which were not included for the development of EndoScreener during 2017 from 2 endoscopy centers. 1451 images of 199 LSTs from 184 patients were obtained from July 2015 to January 2019. 82 videos of SSA/Ps based on pathological diagnosis from 26 patients were obtained from September 2018 to January 2019, each SSA/Ps video was cut into clip from the first frame of its appearance till the last frame it disappeared. The average length of the videos was 17.99-second-long. All the images and videos in the database were acquired from Olympus EVIS LUCERA CV260 (SL)/CV290 (SL) and Fujifilm VP-4450 HD and adapted high-quality and high definition colonoscopes.

Basic demographic characteristics including gender and age; the sizes, locations and histological results of each lesion were illustrated.

We used the CADe system to process each image of LSTs dataset and video clips of SSA/Ps datasets, the system provided a per-pixel labeling of its detected area. The evaluation of the algorithm is based on the consensus among a 3-person panel of senior endoscopists in our center who carefully re-checked each image of the labeled LSTs dataset and each frame of the labeled SSA/Ps video dataset. For image analysis on LSTs, the panel of experienced endoscopists recorded the number of correctly labeled LSTs missed LSTs. Then the panel labeled the border of each LST by hand. For SSA/Ps video assessment, the panel of experienced endoscopists carefully re-checked each labelled frame in the video and recorded the number of correctly labeled polyps and missed polyps. Authors had no access to information that could identify individual participants during or after data collection.

This study was reviewed and approved by institutional review board (Ethics committee) of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital on May 17, 2017.

Written informed consents were obtained from all individuals who were detected LSTs and SSA/Ps during colonoscopy and approved to provide the lesions' images and videos for this study.

All methods were carried out in accordance with relevant regulations of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital.

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

Statistical analysis {#sec010}
--------------------

The main outcome is per-image or per-frame sensitivity and per-lesion sensitivity. The secondary outcome is ratio of correctly labeled area.

If the label of algorithm detection is on an actual lesion (LSTs or SSA/Ps according to the tested datasets), then it is considered a true positive (TP) and only one true positive will be counted for each actual lesion, regardless of how many algorithm labels fall on that lesion. The absence of the algorithm label on an actual lesion is counted as one false negative (FN). Therefore, the total number of true positives and false negatives is the total number of lesion appearance in the validation images or frames. Therefore, per-frame sensitivity was defined as TP divided by total number of polyp appearances = TP / (TP+FN). This is the commonly accepted statistical method for evaluating image detection\[[@pone.0231880.ref020]\].

Because in real clinical setting, intermittent detections could also lead to an effective notice to the endoscopist and thus to avoid a miss diagnosis, we used per-lesion sensitivity to show the pragmatic detection capability of the CADe system. The per-lesion sensitivity is defined as the number of lesions correctly detected by the algorithm in at least one frame divided by the total number of actual lesions.

To measure how well the algorithm can detect the full range of an LST, we also measured the coverage ratio of correctly labeled area, which is defined as the number of pixels of the correctly labeled area which were confirmed by the endoscopist-panel, divided by the number of pixels of the panel-labeled area of each lesion on each frame.

Results {#sec011}
=======

Baseline data of the tested datasets ([Table 1](#pone.0231880.t001){ref-type="table"}) {#sec012}
--------------------------------------------------------------------------------------

10.1371/journal.pone.0231880.t001

###### Baseline information.

![](pone.0231880.t001){#pone.0231880.t001g}

                                                               LST Images Dataset                                                                                                                                                                                   SSA Videos Dataset
  ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Data acquisition**[^a^](#t001fn001){ref-type="table-fn"}   July2015-January2019                                                                                                                                                                                 September2018- January 2019
  **Content**[^b^](#t001fn002){ref-type="table-fn"}            1451 images containing LST                                                                                                                                                                           82 colonoscopy video clips, each with a SSA appearing from the beginning until the end. 12.59 min in total and 17.99s per polyp on average.
  **Device**[^c^](#t001fn003){ref-type="table-fn"}             Olympus and Fujifilm                                                                                                                                                                                 Olympus and Fujifilm
  **Patient demographics**                                     184 patients,92(50.00%) female; age, mean(s.d.):63.11(11.47)                                                                                                                                         26 patients,7(26.92%) female; age, mean(s.d.):50.81(10.07)
  **Polyp histology**                                          Total LST number 199(100%) Carcinoma 24(12.06%) SSAP 16(8.04%) Adenomatous 148(74.37%) Advanced Adenoma 77(38.69%) Hyperplastic and Inflammatory 11(5.53%)                                           Total SSA/Ps number 42(100%) SSAP 42(100%)
  **Polyp location**                                           Rectum 76(38.19%) Sigmoid colon 25(12.56%) Descending colon, including splenic flexure 11(5.53%) Transverse colon 31(15.58%) Ascending colon, including hepatic flexure 42(21.11%) Cecum 14(7.04%)   Rectum 9(21.43%) Sigmoid colon 11(26.19%) Descending colon, including splenic flexure 3(7.14%) Transverse colon 11(26.19%) Ascending colon, including hepatic flexure 7(16.67%) Cecum 1(2.38%)
  Polyp size (cm)                                              size, mean(s.d.):2.33(1.13)                                                                                                                                                                          Small (≤0.5) 29(69.05%) Moderate (\>0.5&\< = 1) 12(28.57%) Large (\>1) 1(2.38%)

^a^All datasets were acquired from the Endoscopy Center of Sichuan Provincial People's Hospital of China and The Affiliated Hospital of Southwest Medical University.

^b^Resolution of images and videos are 704 × 576, 1,920 × 1,080 or 1,280 × 1,024.

^c^Olympus EVIS LUCERA CV260 (SL)/CV290 (SL) and Fujifilm 4450 HD. NA.

In the LSTs image dataset, there were 1451 images containing LSTs of 199 LSTs lesions from 184 patients, among which 90 (50.00%) were female, and the mean age was 63.11±11.47(standard deviation, s.d.). There were 24 carcinomas (12.06%), 16 SSA/Ps (8.04%), 148 conventional adenomas (74.37%), 77 advanced adenomas (38.69%), and 11 hyperplastic or inflammatory component (5.53%). The average diameter of all the LSTs was 2.33±1.13cm.

In the SSA/Ps Video Dataset, there were 82 colonoscopy video clips of 42 SSA/Ps lesions with 18885 frames in total, each with an SSA/Ps appearing from the beginning until the end. The length of the dataset is 12.59 minutes in total and 17.99s per lesion on average. These videos were obtained from 26 patients, including 7 females (26.92%). The mean age was 50.81±10.07. All of the SSA/Ps were Is in morphology according to Paris classification system.

In the SSA/Ps video dataset, there are 29 (69.05%) diminutive lesions (≤0.5cm), 12 (28.57%) small lesions (\<0.5cm, \< = 1cm), and one (2.38%) large lesion. Other baseline information are presented in [Table 1](#pone.0231880.t001){ref-type="table"}.

The detection sensitivity and ratio of correctly labeled area on LSTs ([Table 2](#pone.0231880.t002){ref-type="table"}) {#sec013}
-----------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0231880.t002

###### Detection sensitivity for LSTs.

![](pone.0231880.t002){#pone.0231880.t002g}

  LST Type                     LST-G(H)   LST-G(M)   LST-NG(F)   LST-NG(PD)   Total
  ---------------------------- ---------- ---------- ----------- ------------ --------
  **Per-image sensitivity**    93.97%     98.72%     85.71%      85.71%       94.07%
  **Per-lesion sensitivity**   100.00%    100.00%    98.31%      80.00%       98.99%
  **Labeled Area**             35.66%     41.49%     35.6%       43.47%       39.41%

LSTs were categorized into 4 subgroups which are LST-G(H), LST-G(M), LST-NG(F), and LST-NG(PD), the per-image sensitivity of each subgroup was 93.97% (343/365), 98.72% (692/701), 85.71% (324/378) and 85.71% (6/7), while the per-lesion sensitivity of each subgroup was 100.00% (71/71), 100.00% (64/64), 98.31% (58/59) and 80.00% (4/5). The overall per-image sensitivity and per-lesion sensitivity of LSTs were 94.07% (1365/1451) and 98.99% (197/199) respectively. 2 lesions were missed by CADe system in LST-NG(F) and LST-NG(PD) subgroup separately.

The ratio of correctly labeled area for each subgroup was LST-G(H) 35.66%, LST-G(M) 41.49%, LST-NG(F) 35.6%, LST-NG(PD) 43.47%.

The detection sensitivity on SSA/Ps ([Table 3](#pone.0231880.t003){ref-type="table"}) {#sec014}
-------------------------------------------------------------------------------------

10.1371/journal.pone.0231880.t003

###### Detection sensitivity for SSA/Ps.

![](pone.0231880.t003){#pone.0231880.t003g}

  SSAP Size                    Small (≤0.5)   Moderate (\>0.5&\<=1)   Large (\>1)   Total
  ---------------------------- -------------- ----------------------- ------------- ---------
  **Per-frame sensitivity**    80.29%         92.90%                  86.29%        84.10%
  **Per-lesion sensitivity**   100.00%        100.00%                 100.00%       100.00%

According to the size, the SSA/Ps was classified into 3 subtypes: diminutive (≤0.5cm), small (\>0.5cm&≤1cm) and large (\>1cm), the CADe system had achieved a per-frame sensitivity of each subgroup as 80.29% (10356/12899), 92.90% (5080/5468), 86.29% (447/518). The per-lesion sensitivity for each subgroup was 100.00% (29/29), 100.00% (12/12) and 100.00% (1/1) respectively. The overall per-frame sensitivity and per-lesion sensitivity of SSA/Ps were 84.10% (15883/18885) and 100.00% (42/42).

Discussion {#sec015}
==========

CRC is one of the leading causes of cancer related death\[[@pone.0231880.ref021], [@pone.0231880.ref022]\] and is a major public health issue given its high incidence and mortality rate. Screening colonoscopies have allowed a significant decrease of mortality rate and incidence of CRC in adults (by 51% and 32%, respectively). colonoscopy has also allowed an increase in 5-year survival rate in CRC, mainly as a result of early detection as well as removal of precancerous lesions\[[@pone.0231880.ref023]\]. Missed precancerous lesions, including conventional adenomas, SSA/Ps as well as LSTs with various pathology, during colonoscopy might lead to subsequent colorectal cancer. Miss diagnosis of any precancerous lesions should be decreased because evidence has shown that less interval cancer could be expected under endoscopists with high adenoma detection rate (ADR)\[[@pone.0231880.ref024], [@pone.0231880.ref025]\]. Although conventional adenomatous polyps with a protruding morphology and redder color contributes the majority of ADR, the detection of non-polypoid LSTs and isochromatic SSA/Ps is equally important because they are even more susceptible to be missed\[[@pone.0231880.ref006]\]and some of them are more risky for malignant transformation. Given the importance of better identification of any precancerous lesions during colonoscopy, tremendous efforts from both hardware engineers and clinicians have been put to make lesions more visible to the endoscopists\[[@pone.0231880.ref026]\], However, endoscopists still miss a large portion of precancerous lesions within the screen, for both lesions with non-obvious visual features and lesions that briefly flashed across the screen. These conditions are very challenging even for experienced endoscopists, because humans are always susceptible to "inattentional blindness", "change blindness", visual gaze pattern, fatigue, inter-observer variabilities or any distractions \[[@pone.0231880.ref018], [@pone.0231880.ref027], [@pone.0231880.ref028], [@pone.0231880.ref029], [@pone.0231880.ref030], [@pone.0231880.ref031], [@pone.0231880.ref032]\]. Till now, only second-observer strategies seem helpful to decrease the miss rate of visible polyps for low ADR detectors\[[@pone.0231880.ref026], [@pone.0231880.ref033]\]. However, adding a second human observer might not completely overcome the challenges.

In comparison with human observer, high-performance CADe has high reproducibility, fidelity and uniformity\[[@pone.0231880.ref034]\]. These advantages are especially important for detecting lesions that are non-obvious, briefly visible or partially occluded.

Therefore, it is crucially important to investigate the detection performance exclusively on LSTs and SSA/Ps of any CADe system which was developed for screening early cancers and pre-cancerous lesions, because if a CADe system is only capable to detect polypoid lesions, then its clinical value for decreasing interval cancer is inadequate\[[@pone.0231880.ref019]\]. In the preliminary technical study, we have considered the importance of identifying the local features of a lesion, as pattern of pits and micro-vessels, and thus to build an algorithm that relies less on overall morphology\[[@pone.0231880.ref019]\] This strategy is especially helpful for identifying flat lesions. Moreover, when a lesion flashed across the edge of the screen or partially behind a fold, an algorithm that is trained more on local features and does not rely on the full appearance may still detect it by capturing the detailed features\[[@pone.0231880.ref019]\]. Therefore, such CADe system should be assumed to have a good performance in detecting LSTs and SSA/Ps.

In this study, it is easy for the CADe system to detect the LST-G due to multiple polypoid granules. As a result, the 93.97% per-frame sensitivity for LST-G-H (homogeneous type) and 98.72% per-frame sensitivity for LST-G-M (nodular mixed type) was comparable with the per-frame sensitivity for all kinds of polyps in our preliminary study\[[@pone.0231880.ref019]\]. However, LST-NG is difficult to detect because of the absence of any polypoid protuberance. Nevertheless, the surface texture of LST-NG is distinguishable because most of the LSTs are conventional adenomas in pathology\[[@pone.0231880.ref006]\] and should have the same micro-surface features. The CADe system achieved an 85.71% per-frame sensitivity for LST-NG-F (flat type), 85.71% for LST-NG-PD (pseudo-depressed type), the system missed one lesion in each subgroup.

The ratio of correctly labeled area for the 4 subgroups ranges from 35.6% to 43.47%. The CADe system detected well on the protruding part and the margin. Moreover, when lesion is observed at a close distance, detailed micro-surface structures are identifiable, the CADe system could also detect well on the smooth regions (Figs [2](#pone.0231880.g002){ref-type="fig"} and [3](#pone.0231880.g003){ref-type="fig"}). However, the CADe system failed to completely label the smooth area when a lesion was photographed in far distance when micro-surface structures is visually indistinguishable, it was also challenging for the system to detect the smooth area when the color of the lesion was similar to the background. This is attributed to inadequate visual features. New technology and detection strategy are needed to be deployed to better identify flat and isochromatic lesions that lie far from the camera. Noteworthy, although partially tagged, the alerts generated by the CADe system may still effectively notice the endoscopist and avoid a miss during real clinical setting.

![Detection labeling of CADe system on LSTs with different morphology.\
Green tags are per-pixel predictions of the system in 4 subgroups of LSTs.](pone.0231880.g002){#pone.0231880.g002}

![Detection labeling of CADe system on LSTs with different pathology.\
Green tags are per-pixel predictions of the system on LSTs with different pathology, as hyperplastic, inflammatory, tubular adenoma, villous adenoma, serrated adenoma and adenocarcinoma.](pone.0231880.g003){#pone.0231880.g003}

SSA/Ps are usually flat with an unclear boundary, the color the SSA/Ps are commonly whitish or isochromatic to the background, the micro-surface structures are similar with hyperplastic polyps under white light colonoscopy\[[@pone.0231880.ref035], [@pone.0231880.ref036]\]. Hence, the overall per-frame sensitivity was no more than 90%, the 80.29% sensitivity ([S1](#pone.0231880.s001){ref-type="supplementary-material"}--[S4](#pone.0231880.s004){ref-type="supplementary-material"} Videos) for small SSA/Ps subgroup was much lower than the 91.64% sensitivity for all kinds of polyps in the preliminary study\[[@pone.0231880.ref019]\]. The per-lesion sensitivity was 100.0%, nevertheless, the system might miss a briefly visible lesion because it misses one fifth of the frames. Therefore, it is important to improve the detection performance by adding more training data for the CADe system to "learn" the unique II-O pit and varicose microvascular vessel (VMV)\[[@pone.0231880.ref037]\] of SSA/Ps. Nevertheless, the performance was consistent with the previous technical study, the same CADe system with such a sensitivity for SSA/Ps has increased the deetction rate of diminutive polyps significantly\[[@pone.0231880.ref004]\]\[[@pone.0231880.ref018]\].

However, although adding more training data might be helpful for the CADe system to distinguish subtle inter-class visual features, it will be extremely difficult to obtain a marginal benefit as well as to suppress false positive rate, because when a lesion lies far from the camera, it is challenging for any CADe system or human expert to be specific due to inadequate pixels in the image. Further improvement may be obtained by double-AI CADe system, of which one AI captures local feature of definite lesions which lie close, a second AI independently captures other features of suspected lesions which lie far. Therefore, such double-AI strategy should be more specific for definite lesions and won't compromise the sensitivity for suspected lesion which lies far. Moreover, the distinguished display of definite and suspected lesions could be more comprehensible, and endoscopists can rely on the new system instead of being confused by false alarms or dissatisfied by the insufficient sensitivity for suspected lesions.

In addition, it is important to notice that the current CADe system should be used as a supplement quality assurance tool, because none of them has achieved 100% accuracy. The endoscopists should carefully inspect the colon firstly by themselves instead of fully relying on the detection of the system. The users should be aware of the system-undetected lesions with a basic attention. Therefore, it is crucially important for a CADe system to be well developed and rigorously validated. On one hand, if and only if a CADe system has a good performance to detect non-obvious lesions, it could be considered clinical helpful. On the other hand, the validation dataset of such system should be representative with a large sample size and various target lesions. Moreover, the validation dataset should be obtained from real clinical setting and should contains consecutive unselected unaltered images or videos after the development of the algorithm. Only this, the result, i.e sensitivity and specificity, of the system's performance is meaningful\[[@pone.0231880.ref019]\] and the endoscopist will accurately know how much he can rely on a CADe system. Last but not the least, a post-colonoscopy double check of the system labeled videos by senior endoscopists should be considered to make sure full benefit of the patients.

This study has several limitations, firstly, there were not sufficient samples of LST-NG-PD images and large size SSA/Ps videos, the detection result might not be generalizable for these subtypes, more data should be added to evaluating the detection performance of the CADe system on these subtypes. Secondly, as a limitation of current calculation power of GPU, the current system can only extract a small portion of pixels from these lesions and thus might miss some detailed characteristics after extraction. Therefore, the system might not be so sensitive for lesions lie far from the camera when the number of pixels is inadequate, this will be addressed along with the hardware development. Thirdly, we did not assess the specificity of the system in this study, because the algorithm was unchanged as in the preliminary study\[[@pone.0231880.ref019]\], in which the specificity has been tested on larger image and video datasets.

Conclusion {#sec016}
==========

The local-feature-prioritized polyp detection CADe system could detect LSTs and SSA/Ps with a high sensitivity which indicates it might be a promising quality assurance during colonoscopy to reducing miss diagnosis of easy-to-miss precancerous lesions along with conventional polyps and thus has the potential to decrease the risk of interval cancer. The impact of such CADe system on the detection of LSTs and SSA/Ps in real clinical setting should be specifically investigated in large-scaled clinical trials.
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4\. Thank you for stating the following in the Competing Interests section: \"I have read the journal\'s policy and the authors of this manuscript have the following competing interests:The CADe system (EndoScreener) was developed by Shanghai Wision AI Co., Ltd. The system was provided free-of-charge for this study. Employees in the company were not involved in the study in any way, including in study design, statistical analysis or manuscript writing.\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

5\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

6\. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Colonoscopy is the gold standard for detecting and removing lesions to prevent cancer. Unfortunately, the miss rate can be as high as 25% even for adenomatous polyps and even higher for LST and SSA/P. The authors have developed an automated system to detect lesions. They test whether this system permits LST and SSA/P to be reliably detected. The data indicate the system improves detection but still needs to be perfected. A few concerns need to be addressed.

Major

1\) For a broad audience, much more information needs to be provided regarding the basics of colorectal cancer and image analysis. For example, a figure showing different pathologies would be invaluable.

2\) Define all terms and abbreviations when first used.

3\) The Discussion should address how this work could impact clinical practice.

Minor

1\) Intro - \"alone\" should be \"along\"

2\) Intro - \"literatures\" should be \"studies\"

3\) Methods - averagely is not a word

4\) Discussion - \"caner\" should be \"cancer\"

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.

• A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.

• An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Answer: we have modified the manuscript according to PLOS ONE style.

2\. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (<http://learn.aje.com/plos/>) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website ([www.editage.com](http://www.editage.com)) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

• The name of the colleague or the details of the professional service that edited your manuscript

• A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a \*supporting information\* file)

• A clean copy of the edited manuscript (uploaded as the new \*manuscript\* file)

Answer: Thanks for the recommendation. We've made some edits to the manuscript, hopefully it is now with decent English. If language is the last problem there, we can have it further finetuned.

2\. In the ethics statement in the Methods and online submission information, please ensure that you have specified the form of consent that you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed).

Written informed consents were obtained from all participants, as modified in the revised manuscript

3\. Thank you for stating the following in the Competing Interests section: \"I have read the journal\'s policy and the authors of this manuscript have the following competing interests:The CADe system (EndoScreener) was developed by Shanghai Wision AI Co., Ltd. The system was provided free-of-charge for this study. Employees in the company were not involved in the study in any way, including in study design, statistical analysis or manuscript writing.\"

We have added this section according to your requirement

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

We have added the statements in the manuscript according to your requirement

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

5\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

We have added a data availability section to declare where the minimal and entire data set underlying the results described in the manuscript can be found

6\. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

We have confirmed the title as "Computer aided detection for laterally spreading tumors and sessile serrated adenomas during colonoscopy"

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Answer: the statistical analysis of the study is a basic validation of sensitivity and specificity, these are very routine metrics, the definitions are consistent with our previous study which published at "Nature Biomedical Engineering 2018;2:741--748", the methodology and definitions are also consistent with other major studies around AI-medicine filed. etc.

Wang P, Xiao X, Glissen Brown JR, et al. Development and validation of a deep-learning algorithm for the detection of polyps during colonoscopy. Nature Biomedical Engineering 2018;2:741--748

Bernal, J. et al. Comparative validation of polyp detection methods in video colonoscopy: results from the MICCAI 2015 endoscopic vision challenge. IEEE Trans. Med. Imaging 36, 1231--1249 (2017).

Bandos AI, Rockette HE, Song T, Gur D. Area under the free response ROC curve (FROC) and a related summary index. Biometrics 2009;65:247--256

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Colonoscopy is the gold standard for detecting and removing lesions to prevent cancer. Unfortunately, the miss rate can be as high as 25% even for adenomatous polyps and even higher for LST and SSA/P. The authors have developed an automated system to detect lesions. They test whether this system permits LST and SSA/P to be reliably detected. The data indicate the system improves detection but still needs to be perfected. A few concerns need to be addressed.

Major

1\) For a broad audience, much more information needs to be provided regarding the basics of colorectal cancer and image analysis. For example, a figure showing different pathologies would be invaluable.

Answer: thanks for the comments. For a broad audience, we added a background introduction at the beginning of the discussion section, as "CRC is one of the leading causes of cancer related death\[ \] \[ \] and is a major public health issue given its high incidence and mortality rate. Screening colonoscopies have allowed a significant decrease of mortality rate and incidence of CRC in adults (by 51% and 32%, respectively). colonoscopy has also allowed an increase in 5-year survival rate in CRC, mainly as a result of early detection as well as removal of precancerous lesion"

and a figure 3 which illustrates the detection performance of CADe system on LSTs with different pathologies.

Fig 3

2\) Define all terms and abbreviations when first used.

Answer: we confirm all terms and abbreviations were defined

3\) The Discussion should address how this work could impact clinical practice.

Answer: we added "Noteworthy, although partially tagged, the alerts generated by the CADe system may still effectively notice the endoscopist and avoid a miss during real clinical setting. " to show the impact of the CADe system on LSTs detection during colonoscopy; we added "Nevertheless, the performance was consistent with the previous technical study, the same CADe system with such a sensitivity for SSA/Ps has increased the deetction rate of diminutive polyps significantly" to show the impact of the CADe system on SSA/Ps detection during colonoscopy

Minor

1\) Intro - \"alone\" should be \"along\"

2\) Intro - \"literatures\" should be \"studies\"

3\) Methods - averagely is not a word

4\) Discussion - \"caner\" should be \"cancer\"

All the typos have been corrected

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

\[1\] American Cancer Society. Cancer Facts and Figures: 2017. Atlanta, Georgia. 2017. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-fgures-2017.html>. Accessed August 15, 2017

\[2\] Fang JY, Zheng S, Jiang B, et al. Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China. Gastrointest Tumors 2014;1:53-75
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Dear Dr. Wang,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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